Literature DB >> 16785112

Botulinum toxin therapy for cervical dystonia.

J Jankovic1.   

Abstract

Cervical dystonia (CD) is the most common form of focal dystonia treated with botulinum toxin (BoNT) injections. BoNT has been shown in numerous clinical trials to correct the abnormal posture and movement and to markedly reduce pain associated with CD. In addition, BoNT has favorably modified the natural history of the disease by preventing contractures and other complications of CD, such as secondary degenerative changes of the cervical spine and associated radiculopathy. In a long-term follow-up of patients treated for up to 20 years, the duration of response appears to be sustained and the risk of immunoresistance due to blocking antibodies is relatively small. This review provides and update on the treatment of CD with BoNT type A (BOTOX, Dysport, Xeomin and BoNT type B (Myobloc, NeuroBloc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785112     DOI: 10.1007/bf03033933

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  19 in total

1.  Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.

Authors:  Dirk Dressler; Reiner Benecke
Journal:  Eur Neurol       Date:  2003       Impact factor: 1.710

Review 2.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 3.  Treatment of cervical dystonia with botulinum toxin.

Authors:  Joseph Jankovic
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

4.  Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.

Authors:  R Tintner; R Gross; U F Winzer; K A Smalky; J Jankovic
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

5.  Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.

Authors:  Albert Marchetti; Raf Magar; Leslie Findley; Jan P Larsen; Zvezdan Pirtosek; Evzen Růzicka; Evzen Råuzizka; Robert Jech; Jaroslaw Sławek; Fayyaz Ahmed
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

6.  Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.

Authors:  Dirk Dressler; Hans Bigalke
Journal:  J Neurol       Date:  2005-03-11       Impact factor: 4.849

7.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

Review 8.  Evidence-based review of patient-reported outcomes with botulinum toxin type A.

Authors:  Joseph Jankovic; Alberto Esquenazi; Darcy Fehlings; Fred Freitag; Amy M Lang; Markus Naumann
Journal:  Clin Neuropharmacol       Date:  2004 Sep-Oct       Impact factor: 1.592

9.  Long-term botulinum toxin efficacy, safety, and immunogenicity.

Authors:  Nicte I Mejia; Kevin Dat Vuong; Joseph Jankovic
Journal:  Mov Disord       Date:  2005-05       Impact factor: 10.338

10.  Oropharyngeal swallowing in craniocervical dystonia.

Authors:  C Ertekin; I Aydogdu; Y Seçil; N Kiylioglu; S Tarlaci; T Ozdemirkiran
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

View more
  19 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.

Authors:  A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

Review 3.  An update on the neurologic applications of botulinum toxins.

Authors:  Virgilio Gerald H Evidente; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

Review 4.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.

Authors:  Codrin Lungu; Barbara I Karp; Katharine Alter; Regina Zolbrod; Mark Hallett
Journal:  Mov Disord       Date:  2011-02-01       Impact factor: 10.338

Review 6.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

Review 7.  Clinical relevance of botulinum toxin immunogenicity.

Authors:  Reiner Benecke
Journal:  BioDrugs       Date:  2012-04-01       Impact factor: 5.807

Review 8.  Botulinum toxin: bioweapon & magic drug.

Authors:  Ram Kumar Dhaked; Manglesh Kumar Singh; Padma Singh; Pallavi Gupta
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

9.  An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions.

Authors:  Ricardo Persaud; George Garas; Sanjeev Silva; Constantine Stamatoglou; Paul Chatrath; Kalpesh Patel
Journal:  JRSM Short Rep       Date:  2013-02-12

Review 10.  Long-term efficacy and safety of botulinum toxin injections in dystonia.

Authors:  Juan Ramirez-Castaneda; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2013-02-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.